Cg Oncology, Inc. · NASDAQ:CGON
Cg Oncology — SUO Annual Meeting at AUA 2026
15 slides from Cg Oncology's conference presentation, May 16, 2026
Slide 1: First Results from CORE-008 Cohort CX
For individual reference only. First Results from CORE-008 Cohort CX: The information accessed through this QR code is intended solely for individual reference and should not be Phase 2 Study of Intravesical altered, modified, or reproduced in any way. Cretostimogene Grenadenorepvec with Gemcitabine
Slide 2: Disclosures
Disclosures ‣ Grants: NIH SBIR, DOD, RO1, AUA Care Foundation (mentor). ‣ Clinical trials: CG Oncology, Ferring Pharmaceuticals. ‣ Scientific Advisory Board: Urogen, CG Oncology, Pfizer. ‣ Co-Founder: OncoSTING LLC (www.OncoSTING.com). 2
Slide 3: Rationale for Novel Intravesical Combination Strategies in HR-NMIBC
Rationale for Novel Intravesical Combination Strategies in HR-NMIBC ‣ Efficacy and safety of cretostimogene monotherapy and in combination with pembrolizumab for HR BCG-UR NMIBC and nivolumab for MIBC have been published.1-3 ‣ Novel intravesical therapeutic approaches that leverage complementary mec
Slide 4: Gemcitabine Enhances the Anti-Tumor Activity of Cretostimogene
Gemcitabine Enhances the Anti-Tumor Activity of Cretostimogene ‣ Enhanced in-vitro response to cretostimogene when combined with gemcitabine. ‣ Increased G0/G1 cell- cycle arrest and apoptosis. Steinmetz, Tholmier, Martini, and Mokkapati, 2025 (unpublished data). 4
Slide 5: CORE-008: Phase 2, Multi-Cohort Trial in HR NMIBC
CORE-008: Phase 2, Multi-Cohort Trial in HR NMIBC BCG-Exposed Patients who had prior BCG and either presented with CIS/HGTa recurrence at first evaluation (BCG-resistant), recurred outside of the BCG-unresponsive window following adequate BCG, or recurred within 24 months after inadequate BCG BCG-Un
Slide 6: Treatment & Assessment Schedule
Treatment & Assessment Schedule Legend Cohort CX IVE creto (Concurrent) IVE GEM Cohort CX (Sequential) Concurrent creto+GEM ‣ Re-induction allowed for patients with HG Ta and/or CIS at Month 3 ‣ Assessments include: Cystoscopy & Cytology every 3 months; CT/MRU every 6 months ‣ Clinic-based instillat
Slide 7: Patient Demographics & Baseline Characteristics
Patient Demographics & Baseline Characteristics ‣ All patients enrolled from Patients in Safety Dataset N=55 % Gender Male 43 78.2 the U.S. across multiple 12 21.8 sites of care Female Age (Years) o 80.0% community Mean (Range) 73.1 (54-88) Median (IQR) 75 (66-79) o 20.0% academic Age (Categories) ‣
Slide 8: High-Grade Event-Free Survival at 3 and 6 Months From CORE-008 Cohort CX
High-Grade Event-Free Survival at 3 and 6-Months From CORE-008 Cohort CX (ITT Population) ‣ Median follow-up: 6.6 months Estimated HG-EFS Estimated HG-EFS ‣ No significant differences in HG-EFS at Month 3 at Month 6 by arm 96.0% 89.5% (95% CI: 84.0 – 99.0) (95% CI: 76.6 – 95.5) ‣ Consistent response
Slide 9: High Complete Response Rates Within CIS-Containing Population
High Complete Response Rates Within CIS-Containing Population 92.3% 100 85.7% (95% CI, 74.9% - 99.1%) Complete Response at Any Time (%) (95% CI, 67.3% – 96.0%) 75 IVE gem ‣ Includes BCG-Exposed 50 CR at CR at and BCG-Unresponsive Anytime Anytime (n=24) (n=24) patients 25 Intention to Efficacy Treat
Slide 10: Complete Response Rates Maintained Across Treatment Arms Within CIS-Containing ITT Population
Complete Response Rates Maintained Across Treatment Arms Within CIS-Containing ITT Population Confidence Interval CR Rate % (n/N) (95% CI) Concurrent 83.3% (51.6, 97.9) 10 out of 12 patients 87.5% Sequential (61.7, 98.5) 14 out of 16 patients ‣ High CR rates were achieved in both concurrent and sequ
Slide 11: Favorable and Well-Tolerated Safety Profile
Favorable and Well-Tolerated Safety Profile ‣ 0% Grade ≥ 3 TRAEs, SAEs or Preferred Term Overall deaths ‣ 85.5% (47/55) completed all protocol- (MedDRA v.26.1) (n=55) Grade 1-2 Grade > 3 defined treatments n (%) n (%) Patients with ≥ 1 TRAE 36 (65.5 %) 0 (0) o Arm 1 (Concurrent)- 71.4% (20/28) Treat
Slide 12: CORE-008 Cohort CX: Summary and Conclusions
CORE-008 Cohort CX: Summary and Conclusions ‣ The combination of cretostimogene and gemcitabine demonstrates robust clinical efficacy and safety in BCG-exposed and BCG-unresponsive NMIBC ‣ Comparable efficacy observed in both concurrent and sequential arms ‣ Sequential administration of intravesical
Slide 13: Cohort CX Insights Shaping Phase 3 Trial Under Consideration by SWOG
Cohort CX Insights Shaping Phase 3 Trial Under Consideration by SWOG A Randomized Comparison of Mark Tyson Intravesical Therapies: Professor of Urology A phase 3 study of cretostimogene Mayo Clinic grenadenorepvec/gemcitabine (CRETO- GEM) versus gemcitabine/Docetaxel (GEM DOCE) for the treatment of
Slide 14: Thank You
Thank You All Bladder Cancer Patients and Their Families Key Investigators, Study Coordinators, Nurses For individual reference only. Key Collaborators CG Oncology The information accessed through this QR code is intended solely for individual Aaron Berger, Associated Urologic Specialists, Ying Chen
Slide 15: IP20-04 First Results From CORE-008 Cohort CX
IP20-04 First Results From CORE-008 Cohort CX: Phase 2 Study of Intravesical Cretostimogene Grenadenorepvec with Gemcitabine in Patients with High-Risk BCG-Exposed or BCG-Unresponsive NMIBC Trinity J. Bivalacqua, MD, PhD;1* Aaron Berger, MD;2 Mark D. Tyson, MD, MPH;3 Christopher M. Pieczonka, MD;4 J